Life Sciences

  • January 02, 2026

    Drug Pricing Battles To Watch In 2026

    With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focused on state and federal drug pricing programs.

  • January 02, 2026

    Product Liability Cases To Watch In 2026

    Trials in the massive litigation against social media giants like Facebook are set to start in the New Year, as litigants battle over whether the companies should be held responsible for allegedly designing their platforms to addict youth, causing a bevy of mental health harms, and cases against popular weight loss drugs like Ozempic continue to mount. Here's what else product liability attorneys will be watching in 2026.

  • January 02, 2026

    Patent Litigation Trends To Watch In 2026

    Attorneys are expecting a significant increase in district court litigation after a series of dramatic changes at the U.S. Patent and Trademark Office have made the Patent Trial and Appeal Board less attractive, which is one of the most significant trends for 2026.

  • January 02, 2026

    Antitrust Cases Ahead: Live Nation, Middleman On Trial

    The U.S. Department of Justice and Federal Trade Commission enter 2026 with decisions to make about how to regroup after coming up short in major cases against Google and Meta Platforms.

  • January 02, 2026

    Trade Secret Trends To Watch In 2026

    The landscape of trade secret law could see significant developments in 2026 as courts address the aftermath of astronomical jury awards and navigate jurisdictional tensions surrounding the timing and specifics of trade secret disclosures in litigation.

  • January 02, 2026

    NC Legislation To Watch In 2026: Healthcare Funding In Focus

    A spate of healthcare legislation is on the line as North Carolina lawmakers get ready to return to the General Assembly in January, from tenuous funding for Medicaid and Planned Parenthood to efforts to control the Tar Heel state's skyrocketing healthcare costs.

  • January 02, 2026

    California Cases To Watch In 2026

    Legal experts following California courts in 2026 are tracking high-stakes personal injury, antitrust and copyright battles against giants in the social media, artificial intelligence and entertainment industries, as well as wide-ranging legal disputes arising from Los Angeles wildfires and high-profile appeals pending before the California Supreme Court.

  • January 02, 2026

    Patent Policy To Watch In 2026

    After a year of significant shifts in U.S. Patent and Trademark Office policy on patent reviews and patent eligibility, attorneys will be closely following how the changes play out in 2026, along with proposals for further moves, and whether Congress decides to weigh in on patents.

  • January 02, 2026

    North Carolina Cases To Watch In 2026

    In the new year, North Carolina state and federal courts are set to consider the intricacies of class action certification at the behest of thousands of fast-food workers and whether Chinese company TikTok Inc. is deliberately designing the app to addict children.

  • January 02, 2026

    New Jersey Cases To Watch In 2026

    In the coming year, New Jersey litigators will be watching for the outcome of an appeal in a constitutional challenge to school segregation and an employment discrimination case brought by a former Johnson & Johnson attorney. 

  • January 02, 2026

    What To Watch In Massachusetts Courts In 2026

    Massachusetts attorneys have their eye on Trump administration policy challenges, state ballot question disputes and False Claims Act enforcement shifts as the calendar turns to 2026.

  • January 02, 2026

    SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026

    The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as well as bellwether trials in multidistrict litigation concerning social media's effects on mental health and allegations of price-fixing in the generic-drug industry.

  • January 02, 2026

    Pennsylvania Cases To Watch In 2026

    As winter's chill rings in the new year, several high-profile cases are set to heat up Pennsylvania's dockets in 2026, including disciplinary charges against a judge associated with rapper Meek Mill, a pending appeals decision on the lawfulness of semiautomatic rifles, and Philadelphia's quest to hold pharmacy benefit managers accountable for the opioid epidemic.

  • January 02, 2026

    Patent Cases To Watch In 2026

    The U.S. Supreme Court is considering whether to weigh in on generic-drug skinny labels, while the Federal Circuit is examining an effort by the U.S. Patent and Trademark Office to shield decisions from review. Here's a look at those cases and others that attorneys will be tracking in 2026.

  • January 02, 2026

    The High-Stakes Healthcare AI Battles To Watch In 2026

    Courts across the country are set to hear a wave of litigation in the coming year that will begin to draw the legal boundaries around artificial intelligence in healthcare and the life sciences. Law360 spoke with legal experts about the high-stakes AI litigation set to unfold in 2026.

  • January 01, 2026

    4 High Court Cases To Watch This Spring

    The U.S. Supreme Court justices will return from the winter holidays to tackle several constitutional disputes that range from who is entitled to birthright citizenship to whether transgender individuals are entitled to heightened levels of protection from discrimination. 

  • January 01, 2026

    Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook

    In 2025, President Donald Trump put 20 district and six circuit judges on the federal bench. In the year ahead, a fight over home state senators' ability to block district court picks could make it more difficult for him to match that record.

  • January 01, 2026

    BigLaw Leaders Tackle Growth, AI, Remote Work In New Year

    Rapid business growth, cultural changes caused by remote work and generative AI are creating challenges and opportunities for law firm leaders going into the New Year. Here, seven top firm leaders share what’s running through their minds as they lie awake at night.

  • December 24, 2025

    Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B

    French pharmaceutical giant Sanofi SA said Wednesday that it will buy Dynavax Technologies, a U.S. vaccine developer, for $2.2 billion in a recommended cash deal to expand its adult immunization products.

  • December 23, 2025

    Top Illinois Decisions Of 2025

    State and federal courts have handed down rulings in Illinois cases this year that made clear plaintiffs must allege concrete injury for common law standing, narrowed the scope of the federal anti-kickback statute and laid out a new standard for certifying collective actions.

  • December 23, 2025

    3 Federal Circuit Clashes To Watch In January

    The Federal Circuit is set to hear several intellectual property cases in January, including one over a nine-figure patent judgment against cybersecurity company Gen Digital tied to a contempt finding against a major law firm that represented it, and another over the tech industry's long-running crusade against patent review denials based on related litigation.

  • December 23, 2025

    Philly Joins MDL Against Drug Cos., PBMs Over Insulin Prices

    Philadelphia on Tuesday sued drug manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with several pharmacy benefit managers, joining multidistrict litigation in New Jersey federal court accusing the companies of illegally inflating the price of insulin.

  • December 23, 2025

    Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'

    Amarin Pharma Inc. on Tuesday urged the U.S. Supreme Court to reject the U.S. solicitor general's call to hear a patent case involving generic drug "skinny labels," saying the dispute over the company's heart drug Vascepa deals with factual issues not suitable for high court review.

  • December 23, 2025

    AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit

    Medical device provider AdaptHealth Corp. has agreed to pay $35 million to settle a lawsuit accusing it of deceiving shareholders about its revenue projections as it "routinely engaged in improper and unethical tactics to inflate sales numbers." 

  • December 23, 2025

    Dem Sens. Blast Idea Of Charging Value-Based Patent Fees

    A group of Democratic U.S. senators has asked Commerce Secretary Howard Lutnick not to move forward with a proposed overhaul of the U.S. patent fee system that reportedly would implement fees based on a patent's value, saying such changes would create a "prohibitive bar to innovation for start-ups and other small-to-mid-size businesses."

Expert Analysis

  • 5 Crisis Lawyering Skills For An Age Of Uncertainty

    Author Photo

    As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.

  • Anticipating FTC's Shift On Unfair Competition Enforcement

    Author Photo

    As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

  • Opinion

    It's Time For The Judiciary To Fix Its Cybersecurity Problem

    Author Photo

    After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne.

  • Series

    Writing Novels Makes Me A Better Lawyer

    Author Photo

    Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.

  • SDNY OpenAI Order Clarifies Preservation Standards For AI

    Author Photo

    The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

  • Trends In Post-Grant Practice Since USPTO Denial Guidance

    Author Photo

    Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.